Bristol Myers Squibb Co
Bristol Myers Squibb Co returns on capital
Annual and trailing 12-month returns on invested capital, equity and assets.
ROIC
% · Annual / TTM
Operating income is unavailable in the extracted statements for this period.
ROCE
% · Annual / TTM
Operating income is unavailable in the extracted statements for this period.
ROIIC
% · Annual / TTM
Operating income is unavailable in the extracted statements for this period.
ROE
% · Annual / TTM
ROA
% · Annual / TTM
ROIC − WACC
Percentage points · Scenario
Operating income is unavailable in the extracted statements for this period.
Quarterly data
| Fiscal period | Ended | ROIC% | ROCE% | ROIIC% | ROE% | ROA% | ROIC − WACCPercentage points |
|---|---|---|---|---|---|---|---|
| FY 2026 Q2 | Jun 30, 2026 | — | — | — | 46.7% | 10.18% | — |
| FY 2026 Q1 | Mar 31, 2026 | — | — | — | 38.84% | 8.13% | — |
| FY 2025 Q4 | Dec 31, 2025 | — | — | — | 40.53% | 7.72% | — |
| FY 2025 Q3 | Sep 30, 2025 | — | — | — | 33.84% | 6.34% | — |
| FY 2025 Q2 | Jun 30, 2025 | — | — | — | 29.31% | 5.33% | — |
| FY 2025 Q1 | Mar 31, 2025 | — | — | — | 31.99% | 5.66% | — |
| FY 2024 Q4 | Dec 31, 2024 | — | — | — | -39.1% | -9.53% | — |
| FY 2024 Q3 | Sep 30, 2024 | — | — | — | -31.46% | -7.85% | — |
| FY 2024 Q2 | Jun 30, 2024 | — | — | — | -26.7% | -6.95% | — |
| FY 2024 Q1 | Mar 31, 2024 | — | — | — | -25.45% | -6.36% | — |
| FY 2023 Q4 | Dec 31, 2023 | — | — | — | 26.53% | 8.36% | — |
| FY 2023 Q3 | Sep 30, 2023 | — | — | — | 26.87% | 8.75% | — |
| FY 2023 Q2 | Jun 30, 2023 | — | — | — | 24.66% | 8.22% | — |
| FY 2023 Q1 | Mar 31, 2023 | — | — | — | 23.06% | 7.41% | — |
| FY 2022 Q4 | Dec 31, 2022 | — | — | — | 18.88% | 6.14% | — |
| FY 2022 Q3 | Sep 30, 2022 | — | — | — | 19.11% | 6.39% | — |
| FY 2022 Q2 | Jun 30, 2022 | — | — | — | 19.07% | 6.27% | — |
| FY 2022 Q1 | Mar 31, 2022 | — | — | — | 18.07% | 5.8% | — |
| FY 2021 Q4 | Dec 31, 2021 | — | — | — | 18.96% | 6.14% | — |
| FY 2021 Q3 | Sep 30, 2021 | — | — | — | -12.37% | -4.57% | — |
| FY 2021 Q2 | Jun 30, 2021 | — | — | — | -11.83% | -4.25% | — |
| FY 2021 Q1 | Mar 31, 2021 | — | — | — | -14.21% | -5.15% | — |
| FY 2020 Q4 | Dec 31, 2020 | — | — | — | -20.16% | -7.26% | — |
| FY 2020 Q3 | Sep 30, 2020 | — | — | — | -0.13% | -0.05% | — |
| FY 2020 Q2 | Jun 30, 2020 | — | — | — | -1.73% | -0.61% | — |
| FY 2020 Q1 | Mar 31, 2020 | — | — | — | 2.93% | 1.16% | — |
| FY 2019 Q4 | Dec 31, 2019 | — | — | — | 10.48% | 4.17% | — |
| FY 2019 Q3 | Sep 30, 2019 | — | — | — | 36.15% | 12.41% | — |
| FY 2019 Q2 | Jun 30, 2019 | — | — | — | 43.74% | 14.13% | — |
| FY 2019 Q1 | Mar 31, 2019 | — | — | — | 36.73% | 15.15% | — |
| FY 2018 Q4 | Dec 31, 2018 | — | — | — | 38.18% | 14.36% | — |
| FY 2018 Q3 | Sep 30, 2018 | — | — | — | 10.08% | 4.23% | — |
| FY 2018 Q2 | Jun 30, 2018 | — | — | — | 2.78% | 1.14% | — |
| FY 2018 Q1 | Mar 31, 2018 | — | — | — | 6.76% | 2.78% | — |
| FY 2017 Q4 | Dec 31, 2017 | — | — | — | 7.21% | 2.99% | — |
| FY 2017 Q3 | Sep 30, 2017 | — | — | — | 27.83% | 12.49% | — |
| FY 2017 Q2 | Jun 30, 2017 | — | — | — | 30.97% | 13.85% | — |
| FY 2017 Q1 | Mar 31, 2017 | — | — | — | 33.58% | 14.92% | — |
| FY 2016 Q4 | Dec 31, 2016 | — | — | — | 29.28% | 13.62% | — |
| FY 2016 Q3 | Sep 30, 2016 | — | — | — | 21.93% | 10.28% | — |
| FY 2016 Q2 | Jun 30, 2016 | — | — | — | 19.11% | 8.86% | — |
| FY 2016 Q1 | Mar 31, 2016 | — | — | — | 10.52% | 4.81% | — |
| FY 2015 Q4 | Dec 31, 2015 | — | — | — | 10.75% | 4.78% | — |
| FY 2015 Q3 | Sep 30, 2015 | — | — | — | 11.75% | 5.44% | — |
| FY 2015 Q2 | Jun 30, 2015 | — | — | — | 11.76% | 5.47% | — |
| FY 2015 Q1 | Mar 31, 2015 | — | — | — | 14.53% | 6.73% | — |
| FY 2014 Q4 | Dec 31, 2014 | — | — | — | 13.36% | 5.54% | — |
| FY 2014 Q3 | Sep 30, 2014 | — | — | — | 18.19% | 7.73% | — |
| FY 2014 Q2 | Jun 30, 2014 | — | — | — | 18.1% | 7.71% | — |
| FY 2014 Q1 | Mar 31, 2014 | — | — | — | 19.85% | 8.33% | — |
| FY 2013 Q4 | Dec 31, 2013 | — | — | — | 17.81% | 6.88% | — |
| FY 2013 Q3 | Sep 30, 2013 | — | — | — | 19.3% | 7.58% | — |
| FY 2013 Q2 | Jun 30, 2013 | — | — | — | 8.92% | 4% | — |
| FY 2013 Q1 | Mar 31, 2013 | — | — | — | 9.79% | 4.29% | — |
| FY 2012 Q4 | Dec 31, 2012 | — | — | — | 13.25% | 5.69% | — |
| FY 2012 Q3 | Sep 30, 2012 | — | — | — | 12.38% | 5.55% | — |
| FY 2012 Q2 | Jun 30, 2012 | — | — | — | 21.97% | 11.23% | — |
| FY 2012 Q1 | Mar 31, 2012 | — | — | — | 23.62% | 12.09% | — |
| FY 2011 Q4 | Dec 31, 2011 | — | — | — | 23.37% | 11.58% | — |
| FY 2011 Q3 | Sep 30, 2011 | — | — | — | 20.49% | 10.45% | — |
| FY 2011 Q2 | Jun 30, 2011 | — | — | — | 20.71% | 10.56% | — |
| FY 2011 Q1 | Mar 31, 2011 | — | — | — | 21.4% | 10.86% | — |
| FY 2010 Q4 | Dec 31, 2010 | — | — | — | 20.3% | 9.99% | — |
| FY 2010 Q3 | Sep 30, 2010 | — | — | — | 69.82% | 33.88% | — |
| FY 2010 Q2 | Jun 30, 2010 | — | — | — | 71.64% | 35.03% | — |
| FY 2010 Q1 | Mar 31, 2010 | — | — | — | — | — | — |
| FY 2009 Q4 | Dec 31, 2009 | — | — | — | — | — | — |
| FY 2009 Q3 | Sep 30, 2009 | — | — | — | — | — | — |
| FY 2009 Q2 | Jun 30, 2009 | — | — | — | — | — | — |
Sources and calculations
Financial inputs from company filings. Last checked Oct 18, 2026. A dash means missing inputs or an undefined calculation.
Period changes use the preceding fiscal quarter or year. Percentage changes divide by the absolute prior value; a zero or missing baseline has no percentage change. Percentage metrics show changes in percentage points.
Quarterly returns use trailing 12-month earnings and period-end balances averaged with the same fiscal quarter one year earlier. NOPAT uses the reported effective tax rate only when pretax profit is positive and the rate is between 0 and 100%. WACC starts at 7.9%, rounded from the Pharmaceuticals benchmark in NYU Stern · January 2026. It is an editable US sector proxy applied across history, not a company estimate; foreign reporting currencies also need a currency-specific assessment.
Market prices: Yahoo Finance · BMY, USD. Latest completed close Sep 25, 2026. Price data retrieved Sep 28, 2026.
- ROIC
- NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
- ROCE
- Operating income / average (assets − current liabilities) × 100, using period end and one year earlier.
- ROIIC
- Year-over-year change in annual/TTM NOPAT / positive year-over-year change in invested capital × 100. Capital reductions and missing inputs yield unavailable values.
- ROE
- Earnings attributable to owners / average equity attributable to owners × 100, using period end and one year earlier.
- ROA
- Net income / average total assets × 100, using period end and one year earlier.
- ROIC − WACC
- ROIC less your WACC assumption, in percentage points. The same scenario rate is applied across history; it is not a reported or historical company WACC.